IDEAS home Printed from https://ideas.repec.org/a/spr/eujhec/v6y2005i3p197-202.html
   My bibliography  Save this article

The economic and quality of life impact of hypoglycemia

Author

Listed:
  • Jonas Lundkvist
  • Christian Berne
  • Björn Bolinder
  • Linus Jönsson

Abstract

No abstract is available for this item.

Suggested Citation

  • Jonas Lundkvist & Christian Berne & Björn Bolinder & Linus Jönsson, 2005. "The economic and quality of life impact of hypoglycemia," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 6(3), pages 197-202, September.
    • Handle: RePEc:spr:eujhec:v:6:y:2005:i:3:p:197-202
    DOI: 10.1007/s10198-005-0276-3
    as

    Download full text from publisher

    File URL: http://hdl.handle.net/10.1007/s10198-005-0276-3
    Download Restriction: Access to full text is restricted to subscribers.
    File URL: https://libkey.io/10.1007/s10198-005-0276-3?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Maria Alva & Alastair Gray & Borislava Mihaylova & Philip Clarke, 2014. "The Effect Of Diabetes Complications On Health‐Related Quality Of Life: The Importance Of Longitudinal Data To Address Patient Heterogeneity," Health Economics, John Wiley & Sons, Ltd., vol. 23(4), pages 487-500, April.
    2. Shuyan Gu & Yiming Mu & Suodi Zhai & Yuhang Zeng & Xuemei Zhen & Hengjin Dong, 2016. "Cost-Effectiveness of Dapagliflozin versus Acarbose as a Monotherapy in Type 2 Diabetes in China," PLOS ONE, Public Library of Science, vol. 11(11), pages 1-25, November.
    3. Shuyan Gu & Yuhang Zeng & Demin Yu & Xiaoqian Hu & Hengjin Dong, 2016. "Cost-Effectiveness of Saxagliptin versus Acarbose as Second-Line Therapy in Type 2 Diabetes in China," PLOS ONE, Public Library of Science, vol. 11(11), pages 1-21, November.

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:eujhec:v:6:y:2005:i:3:p:197-202. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.